Jiangsu GDK Biotechnology Co Ltd (688670) - Net Assets
Based on the latest financial reports, Jiangsu GDK Biotechnology Co Ltd (688670) has net assets worth CN¥1.08 Billion CNY (≈ $157.56 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.36 Billion ≈ $198.42 Million USD) and total liabilities (CN¥279.22 Million ≈ $40.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is Jiangsu GDK Biotechnology Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.08 Billion |
| % of Total Assets | 79.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -24.79% |
| 10-Year Change | N/A |
| Growth Volatility | 203.79 |
Jiangsu GDK Biotechnology Co Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Jiangsu GDK Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 688670 stock market capitalisation.
Annual Net Assets for Jiangsu GDK Biotechnology Co Ltd (2017–2025)
The table below shows the annual net assets of Jiangsu GDK Biotechnology Co Ltd from 2017 to 2025. Also explore 688670 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.10 Billion ≈ $160.83 Million |
-13.97% |
| 2024-12-31 | CN¥1.28 Billion ≈ $186.95 Million |
-6.82% |
| 2023-12-31 | CN¥1.37 Billion ≈ $200.63 Million |
-6.07% |
| 2022-12-31 | CN¥1.46 Billion ≈ $213.60 Million |
-0.12% |
| 2021-12-31 | CN¥1.46 Billion ≈ $213.84 Million |
+502.62% |
| 2020-12-31 | CN¥242.50 Million ≈ $35.49 Million |
+323.75% |
| 2019-12-31 | CN¥-108.38 Million ≈ $-15.86 Million |
-21.31% |
| 2018-12-31 | CN¥-89.34 Million ≈ $-13.07 Million |
-45.68% |
| 2017-12-31 | CN¥-61.33 Million ≈ $-8.97 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu GDK Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5539404521.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.27 Billion | 115.17% |
| Total Equity | CN¥1.10 Billion | 100.00% |
Jiangsu GDK Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangsu GDK Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Platinum Capital Ltd
AU:PMC
|
$342.65 Million |
|
Career Technology MFG Co Ltd
TW:6153
|
$342.74 Million |
|
Nordic Paper Holding AB
ST:NPAPER
|
$342.74 Million |
|
Beijing Seeyon Internet Software Cp
SHG:688369
|
$342.76 Million |
|
InPlay Oil Corp
TO:IPO
|
$342.38 Million |
|
Dhani Services Limited
NSE:DHANI
|
$342.32 Million |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
$342.23 Million |
|
SMS Electric Co Ltd Zhengzhou
SHE:002857
|
$342.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu GDK Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,277,578,797 to 1,099,114,043, a change of -178,464,754 (-14.0%).
- Net loss of 173,473,600 reduced equity.
- Dividend payments of 1,256,201 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-173.47 Million | -15.78% |
| Dividends Paid | CN¥1.26 Million | -0.11% |
| Other Changes | CN¥-3.73 Million | -0.34% |
| Total Change | CN¥- | -13.97% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu GDK Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥-1.22 | CN¥19.00 | x |
| 2018-12-31 | CN¥-1.28 | CN¥19.00 | x |
| 2019-12-31 | CN¥-1.55 | CN¥19.00 | x |
| 2020-12-31 | CN¥2.63 | CN¥19.00 | x |
| 2021-12-31 | CN¥13.92 | CN¥19.00 | x |
| 2022-12-31 | CN¥11.95 | CN¥19.00 | x |
| 2023-12-31 | CN¥11.20 | CN¥19.00 | x |
| 2024-12-31 | CN¥10.38 | CN¥19.00 | x |
| 2025-12-31 | CN¥8.93 | CN¥19.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu GDK Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -153.20%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.29x
- Recent ROE (-15.78%) is below the historical average (4.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CN¥-26.53 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | CN¥-19.08 Million |
| 2019 | 0.00% | -28.35% | 0.17x | 0.00x | CN¥-8.20 Million |
| 2020 | 63.91% | 26.31% | 0.76x | 3.21x | CN¥130.73 Million |
| 2021 | 5.64% | 21.02% | 0.22x | 1.20x | CN¥-63.68 Million |
| 2022 | 2.85% | 13.04% | 0.17x | 1.25x | CN¥-104.42 Million |
| 2023 | -5.18% | -52.75% | 0.08x | 1.19x | CN¥-208.10 Million |
| 2024 | -7.32% | -115.72% | 0.05x | 1.20x | CN¥-221.26 Million |
| 2025 | -15.78% | -153.20% | 0.08x | 1.29x | CN¥-283.39 Million |
Industry Comparison
This section compares Jiangsu GDK Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $4,104,769,191
- Average return on equity (ROE) among peers: 5.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu GDK Biotechnology Co Ltd (688670) | CN¥1.08 Billion | 0.00% | 0.26x | $342.53 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $148.06 Million | 1.35% | 0.30x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $205.14 Million | 10.08% | 0.94x | $1.40 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $110.32 Million | -17.34% | 4.98x | $584.83 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $208.96 Million | -6.84% | 0.25x | $569.48 Million |
| Chengzhi Shareholding Co Ltd (000990) | $129.07 Million | 18.02% | 0.66x | $1.64 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.55 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $280.69 Million | 10.24% | 0.16x | $1.15 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.80 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.98 Billion | 2.72% | 0.34x | $442.04 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.45 Billion | 14.73% | 0.06x | $1.67 Billion |
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more